Fresenius Medical Care
* For banks, enterprise value is substituted with market cap. Source: Bloomberg Finance L.P.
Fresenius Medical Care appears in the following brand league tables:
2013 brand performance*
* Figures taken on 31st December 2012.
2012 brand performance*
* Figures taken on 31st December 2011.
2011 brand performance*
* Figures taken on 31st December 2010.
2010 brand performance*
* Figures taken on 31st December 2009.
"Creating a future worth living. For people. Worldwide. Every day."
Although Fresenius Medical Care AG was only founded in 1996, its history dates back to the 18th century. In 1462, the first Hirsch-pharmacy was established in Frankfurt am Main, Germany, which, in the 18th century, came under the ownership of the Fresenius family. Dr. Eduard Fresenius himself started with the production of pharmaceuticals in 1912, followed by the establishment of a separate production plant in Bad Homburg. In the 1970s, Fresenius started to expand its business into the dialysis segment, primarily focusing on the production of dialysers. In 1996, finally, Fresenius Medical Care had its IPO at the Frankfurt and New York Stock Exchange and was officially founded. During the early 2000s, the company soon became one of the market leaders within the dialysis business, serving more than 120,000 patients all over the globe. In March 2006, Fresenius acquired the Renal Care Group, Inc., developing and operating dialysis centres across the United States. This acquisition further fostered Fresenius’ position as market leader, resulting in the production of 500 million dialysers in 2007. Until today, Fresenius Medical Care AG has been providing over 30 million dialysis treatment to more than 200,000 patients worldwide.
Dr. Ben J. Lipps, CEO
Dr. Ben J. Lipps serves as Chief Executive Officer of Fresenius Medical Care since 1999. Prior to that, he was CEO of Fresenius Medical Care North America from 1996 to 1999 and of Fresenius U.S. from 1985 to 1996. After earning his master’s degree and doctorate in Chemical Engineering at the Massachusetts Institute of Technology, he led the research team at Dow Chemical that developed the first commercial hollow-fiber artificial kidney at the end of the 1960s.
Michael Brosnan, CFO
Michael Brosnan serves as Chief Financial Officer since January 2010. Previously, he served as Chief Financial Officer of Fresenius Medical Care North America for seven years. He joined the Company in 1998 as Vice President of Finance and Administration for Spectra Renal Management, the Company’s laboratory services organization. Subsequently, he assumed several executive functions at Fresenius Medical Care North America. Prior to joining the Company, he held senior financial positions at Polaroid Corporation and was an audit partner at KPMG.